Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|August 20, 2010

Supplements and Featured Publications

Managed Care Pharmacy and the Evolving Diabetes Treatment Paradigm - Are We Capable of Disease Contr
Volume 16
Issue 7 Suppl

Posttest

Download PDF: Posttest

Articles in this issue

almost 16 years ago

Article

Incretin-Based Therapies in the Management of Type 2 Diabetes: Rationale and Reality in a Managed Care Setting

almost 16 years ago

Article

Participating Faculty

almost 16 years ago

Article

Diabetes Pharmacy Management: Balancing Safety, Cost, and Outcomes

almost 16 years ago

Article

Improving Treatment Success Rates for Type 2 Diabetes: Recommendations for a Changing Environment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC original research policy

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

AJMC original research managerial

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

AJMC Letter to the Editor

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

AJMC original research policy

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

AJMC commentary

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL